DOCSLIB.ORG

HCP Presentation Croatia 15 May 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HCP Presentation Croatia 15 May 2018 Host Cell Protein Conference May 14-16, 2018 Dubrovnik, Croatia The Challenges of Developing HCPs Methods for Vaccines A Risk Based Approach to HCP Monitoring 15 May 2018 Dr. Lee Smith © 2018 GreyRigge Assoc. Ltd. All rights reserved Types of Vaccines & Their Cell Substrate • Inactivated whole virus • Mammalian, Insect • Live attenuated virus • Vero, HEK293, sf9 • Live attenuated viral vector • DNA vaccine • Bacterial culture • E. coli • Subunit or VLP • Subunit or VLP • E. coli, yeast 2 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Live Virus Vaccine Processes • Similar in principle to most biologics, an upstream and a downstream • However, while many processes will have a viral removal step, this is different for a live virus vaccine process WCB Cell Expansion HARVEST ENDONUCLEASE WVS Buf Soln Flush x Ret 10 FILTRATION UF/DF STERILE FILTRATION CHROMATOGRAPHY DRUG SUBSTANCE 3 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Live Virus Vaccine Processes & Host Cell Protein (hcp) • There are a number of stages throughout the process where host cell proteins are removed. • It is likely that hcp co-purify with the virus product. hcp WCB Cell Expansion HARVEST ENDONUCLEASE WVS Buf Soln Flush x Ret 10 FILTRATION UF/DF STERILE FILTRATION CHROMATOGRAPHY DRUG SUBSTANCE 4 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Enveloped Live Virus Expression Live virus expression can be: 1) lytic 2) secreted 3) intracellular The virus, if it buds off the cell membrane, it will incorporate host cell proteins into the envelope of the virus product The product will contain free hcp as well as hcp incorporated into the product Therefore we can’t remove all hcp without removing virus 5 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Enveloped Live Virus Expression cont. The product in the harvest may be surrounded by hcp with also some of the hcp incorporated into the virus envelope. Even when the process removes much of the hcp, some of it will remain in the product. 6 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Host Cell Protein Levels • How much hcp is too much for a vaccine? • There is no specified amount and it is case by case • A risk assessment needs to be made and justified to regulators for the product taking into account: ➢ Vaccine dosing regime such as: • Dose level • number of doses required ➢ For a live infectious virus even a billion particles may represent a small amount of virus protein relative to hcp protein in the product. ➢ A single particle of vaccinia-a virus that forms the basis How much protein? for the smallpox vaccine-weighs only 9 femtograms, or 10 Femtograms per quadrillionths of a gram. particle 1 fg = 0.000000001ug 7 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Typical hcp amounts in a Live Virus Vaccine? It depends on how long the vaccines have been around Measles vaccines first used in vaccination programs in 1960’s Vaccine still being used now Frequently these vaccines might almost be described as formulated harvest What would the hcp content be? Very High? None-the-less, these vaccines are very safe. 8 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Typical hcp amounts in a LiveWCB Virus Vaccine?Cell Expansion HARVEST ENDONUCLEASE WVS Buf Modern vaccines purified Soln Flush through complex DSP x Ret 10 Compared to older vaccines FILTRATION UF/DF STERILE FILTRATION CHROMATOGRAPHY DRUG SUBSTANCE 1-50g/dose! 700g/dose! Wouldn’t recommend this! 9 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved How was 700ug/dose of hcp acceptable? • Primarily there is no benchmark to say it isn’t safe • The hcp vaccine from prior dose ranging studies (the high dose) demonstrated hcp levels caused no adverse events in toxicology and phase I clinical studies • Argued hcp content was linked to vaccine dose due to the hcp being integral within the membrane • All particles may not be infectious; non- infectious particles still contain hcp • Commitment to improve process to remove hcp in lysate as process evolves Plus method didn’t detect all hcp! 10 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Should I use an OTS Host Cell Protein Immunoassay? It depends on the ability of the ELISA kit to detect all of the hcp in the product If the coverage is good then it becomes an option to stay with the OTS ELISA kit 100% Coverage of hcp? 70% Coverage of hcp? 11 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Could I use OTS Host Cell Protein Immunoassay? It depends on the ability of the ELISA kit to detect all of the hcp in the product If the coverage is good then it becomes an option to stay with the OTS ELISA kit 100% Coverage of hcp? 50% Coverage of hcp? What coverage is acceptable? 12 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Determining your Coverage If using immunoassays, a Western/fluorescent 2D blot using the OTS ELISA kit can be used to determine the amount of coverage If the coverage is considered inadequate (we’ve used < 70%) then new serum/antibodies should be prepared Preparation of serum/antibodies for a live viral vaccine product is a significant technical challenge 13 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Preparation of HCP Antigen for Immununisations Null Cell Line Approach – to obtain hcp profile similar to the product Expand the cells, do not infect and process supernatant through the DSP. However, some virus will secrete into Sn so little HCP released. For lytic or non-lytic virus this is a lesser concern. HCP from harvest can then be purified However, the hcp may purify differently to when virus is present 14 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Preparation of HCP Antigen for Immununisations Cont. Cell Lysis & Processing We can expand cells and simply lyse them through Freeze/Thaw or sonication releasing the hcp. These are then processed them through the DSP Cell Expansion Lysis HARVEST ENDONUCLEASE Buf Soln Flush x Ret 10 FILTRATION UF/DF STERILE FILTRATION CHROMATOGRAPHY HCP 15 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Preparation of HCP Antigen for Immununisations Cont. Cell Lysis We can expand cells and simply lyse them and immunize with the crude hcp. Cell Expansion Lysis Crude HCP Depth filtration can be used to remove large particulates from the crude lysate Buf Soln Flush UF/DF with a suitable membrane cutoff can be used to split the x Ret 10 lysate into high and low molecular weight hcp UF/DF 16 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Preparation of HCP Antigen for Immununisations Cont. Low & High wt. lysate Lyse Free HCP Product containing hcp Can characterize on 2D gel to compare lysate with product, including blotting with Ab 17 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Immunisations • The Low & High M. Wt lysate can be immunized separately or in combination • This serum will be immunized in line with an agreed protocol 18 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Immunisations cont. Cascade immunization can be considered if The animals are bled to obtain and Ag components immunodominant test the serum for binding to the hcp & the FT re-immunised 19 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Characterising the Serum The Serum can then be assessed to understand the coverage of product hcp 50%70%+ ✓ 20 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Development of the ELISA & Long-Term Thinking • Once the serum is suitable then the ELISA must be developed • Careful thought must be given to who and how this is developed. Have they suitable quality systems for long term supply? • The method must be developed with a view to long term supply (20 yrs +) • Key reagents such as labels, secondary antibodies • Reference preparation (hcp Ag) • Materials (plates) • Also, will a large amount of polyclonal serum be made and stored long term? • Will new serum be raised on a regular basis and characterised? 21 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved HCP ELISA Method Qualification & Validation If the method is developed externally, the ELISA would then need to be qualified in line with ICH Q2(R1) guidance. Hcp is a impurity that is measured quantitatively. 22 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved HCP ELISA Method Qualification & Validation cont. There will be a hcp standard curve Control samples (H, M, L) The Qualification should focus on putting samples through the standard curve. The Std. curve will be sigmoidal but your samples should be reading off linearly. During Qualification you will determine - Linearity - Precision - Accuracy (or relative bias) - Range - Limit of Quantitation HCPHCP Protein Protein Conc. Conc (ug/mL (ug/mL)) - Specificity 23 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Method Transfer Once the method is developed and qualified, the method must be transferred The transfer would be to a GMP QC laboratory Qualifying QC Lab The QC laboratory would perform the Lab validation This would use the data derived from the qualification as well as routine performance Another data to set acceptance criteira for the Contract Production validation Lab Site The validation would be based upon the same ICH Q2(R1) requirements for a quantitative impurity assay 24 | 15-MAY-2018 © 2018 GreyRigge Assoc. Ltd. All rights reserved Summary • Developing a hcp method for a live viral vaccine brings particular challenges • The levels of host cell protein in a product are case by case and must be justified based upon good scientific rationale, data & a risk based approach • Off the shelf methods are not product specific and may not give an adequate level of hcp coverage for your product and must be assessed • Preparation and characterization of the antigen is pivotal.
Load more

Recommended publications
  • CHO Host Cell Proteins 3Rd Generation
    CHO Host Cell Proteins 3rd Generation Immunoenzymetric Assay for the Measurement of CHO Host Cell Proteins Catalog # F550 Intended Use immunoenzymetric assay (ELISA) method employed in this kit overcomes the limitations of Western blots This kit is intended for use in determining the presence providing on the order of 100 fold better sensitivity. This of host cell protein impurities in products manufactured simple to use, objective, and semi-quantitative ELISA is by expression in the CHO cell line. The kit is for a powerful method to aid in optimal purification process Research and Manufacturing Use Only and is not development, process control, routine quality control, intended for diagnostic use in humans or animals. This and product release testing. This kit is “generic” in the is the 3rd Generation ELISA kit for CHO HCP detection. sense that it is intended to react with essentially all of the Cygnus Technologies continues to market two earlier HCPs that could contaminate the product independent generation kits, Cat #s F015 and CM015 for CHO HCP of the purification process. The antibodies have been detection. While those kits are broadly reactive to CHO generated in goats and affinity purified using CHO HCPs HCPs among all strains and have been successfully found in protein free conditioned media. Western blot, qualified for a range of drug substances, this 3rd both 1 & 2 dimensional, was used as a preliminary Generation assay uses an even more broadly reactive method and established that the antibodies reacted to antibody. The 3rd Generation Cat# F550 kit offers the majority of HCP bands resolved by the PAGE greater sensitivity and a more linear standard curve separation.
    [Show full text]
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Quantification of Host Cell Protein Impurities Using the Agilent 6495C Triple Quadrupole LC/MS
    Application Note Pharma & Biopharma Quantification of Host Cell Protein Impurities using the Agilent 6495C Triple Quadrupole LC/MS Author Abstract Linfeng Wu Agilent Technologies, Inc., This Application Note describes a method for sub-ppm host cell protein quantification in a mAb product. The workflow featured an Agilent AssayMAP Bravo platform, an Agilent 1290 Infinity II LC, and an Agilent 6495C triple quadrupole LC/MS. Introduction Experimental Sample preparation The mAb sample was subjected to Host cell protein (HCP) impurities are Instrumentation denaturation, reduction, alkylation, and low-level protein impurities derived • Agilent AssayMAP Bravo system trypsin digestion using the AssayMAP from the host organisms during the (G5571AA) Bravo system. SIL peptides were biopharmaceutical manufacturing combined at equal molar concentration • Agilent 1290 Infinity II LC including: process. Due to their potential to affect and spiked into the sample digest at product safety and efficacy, HCPs • Agilent 1290 Infinity II high-speed eight different levels (6.25, 12.5, 25, 62.5, must be monitored and controlled in pump (G7120A) 125, 250, 12,500, and 125,000 amol/µg drug products according to regulatory • Agilent 1290 Infinity II per SIL peptide) for quantitative analysis. requirements1. Traditionally, the multisampler (G7167B) with enzyme-linked immunosorbent assay LC/MS analysis sample cooler option (option 100) (ELISA) is the standard method for Samples were analyzed by the 6495C quantifying HCPs in protein therapeutics. • Agilent 1290 Infinity II triple quadrupole LC/MS in dMRM However, ELISA lacks the specificity thermostatted column mode using a nine-minute LC gradient. and coverage to identify and quantify compartment (G7116B) Tables 1 and 2 list detailed experimental individual HCPs.
    [Show full text]
  • Host Cell Protein Assays
    BIOLOGICS TESTING SOLUTIONS Host Cell Protein Assays Charles River works with clients to develop project-specific and platform-specific host cell protein (HCP) assays. Additionally, we serve clients with the characterization of commercially available kits and coverage determination. The type of assay required to determine HCP content is dependent upon the phase of product development. In early process development and early clinical phases, generic assays are normally acceptable. However, once the biopharmaceutical is used in Phase III clinical studies, a validated, product-specific HCP assay is usually required. We can provide clients with assay development and validation, regardless of whether they are in preclinical development or embarking on Phase III studies. What Are Host Cell Proteins? Host cell proteins (HCP) represent a heterogeneous pool of contaminant proteins that are an inevitable impurity of biopharmaceuticals, regardless of whether they are produced by recombinant fermentation or extracted from natural sources. Even after multiple sophisticated purification steps, HCPs may co-purify, or “hitchhike,” with the product, and thus need to be characterized and quantified in drug substance and in downstream purification process (DSP) intermediates. The risk for adverse effects such as immunogenic reaction does not necessarily correlate with the amount of certain host cell proteins, and even traces of an HCP can be highly immunogenic, or may adversely impact product quality over its shelf life. Traditional protein detection methods such as HPLC and total protein stains are not suitable for HCP detection due to insufficient sensitivity and specificity. Consequently, optimized immunoassays (ELISA) and mass spectrometry (MS) methods have established themselves as the methods of choice for the measurement and characterization of HCPs.
    [Show full text]
  • Development of Host Cell Protein Impurities Quantification Methods by Mass Spectrometry to Control the Quality of Biopharmaceuticals Gauthier Husson
    Development of host cell protein impurities quantification methods by mass spectrometry to control the quality of biopharmaceuticals Gauthier Husson To cite this version: Gauthier Husson. Development of host cell protein impurities quantification methods by mass spec- trometry to control the quality of biopharmaceuticals. Analytical chemistry. Université de Strasbourg, 2017. English. NNT : 2017STRAF066. tel-01730667 HAL Id: tel-01730667 https://tel.archives-ouvertes.fr/tel-01730667 Submitted on 13 Mar 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE DES SCIENCES CHIMIQUES UMR 7178 THÈSE présentée par : Gauthier HUSSON soutenue le : 10 novembre 2017 pour obtenir le grade de : Docteur de l’université de Strasbourg Discipline / Spécialité : Chimie / Chimie Analytique DEVELOPMENT OF HOST CELL PROTEIN IMPURITIES QUANTIFICATION METHODS BY MASS SPECTROMETRY TO CONTROL THE QUALITY OF BIOPHARMACEUTICALS THÈSE dirigée par : Dr. VAN DORSSELAER Alain Directeur de recherche, CNRS, Université de Strasbourg, France Pr. BRACEWELL Daniel Professor, University College London, United Kingdom RAPPORTEURS : Dr. FERRO Myriam Directeur de recherche, CEA, Grenoble, France Dr. O’HARA John Director, Characterisation, UCB, Slough, United Kingdom AUTRES MEMBRES DU JURY : Dr. GERVAIS Annick Director PCMD I, ASB, UCB, Braine l’Alleud, Belgium Dr.
    [Show full text]
  • HOST-CELL PROTEIN TESTING: Perspective of Current and Future Techniques
    HOST-CELL PROTEIN TESTING: Perspective of Current and Future Techniques April 23, 2018 Dr. Min Zhao Director, Analytical Services for Biologics Products – CMC Services TABLE OF CONTENTS Introduction............................................................................................................................. 3 Residual HCPs Are Problematic..................................................................................... 3 Regulators Key in on HCPs............................................................................................. 3 HCPs are Abundant, Heterogeneous and Hard to Detect.......................................... 4 Several Testing Options Exist............................................................................................. 4 Best Practices Are EmergIng with New Testing Methods............................................ 5 MS Technology Is the Way of the Future.................................................................... 6 2. VISIT US AT: frontagelab.com © 2018 Frontage Laboratories, Inc. HOST-CELL PROTEIN TESTING: Perspective of Current and Future Techniques Introduction Biologics are produced using living cells or organisms. The living cells can be derived from prokaryotic, eukaryotic, and mammalian cells that are genetically engineered to encode the protein of therapeutic use. During the protein expression process, thousands of endogenous proteins, or host-cell proteins (HCPs), are produced and needed to maintain cellular function and regulation, as well as the protein of interest.
    [Show full text]
  • Protein Aggregation and Host Cell Protein
    INVESTIGATING THE IMMUNOGENICITY OF THERAPEUTIC PROTEINS: PROTEIN AGGREGATION AND HOST CELL PROTEIN IMPURITIES A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2016 Kirsty D Ratanji Table of Contents 1 Introduction 15 1.1 Review article: Immunogenicity of therapeutic proteins: Influence of aggregation 15 1.1.1 Abstract 17 1.1.2 Introduction 18 1.1.3 Protein aggregation 19 1.1.4 Methods to reduce aggregation 24 1.1.5 Immunogenicity of biotherapeutics 26 1.1.6 Clinical examples of aggregation associated immunogenicity 32 1.1.7 Screening for aggregation and immunogenicity 38 1.1.8 Concluding remarks 44 1.2 Introduction (cont’d) 45 1.2.1 Immunogenicity testing 45 1.2.2 Biophysical methods for aggregate analysis 52 1.2.3 Thesis aims 59 1.3 Alternative format 63 2 Paper 1: Producing and characterising subvisible protein aggregates for immunogenicity studies 65 2.1 Abbreviations 66 2.2 Abstract 67 2.3 Introduction 68 2.4 Methods 71 2.5 Results 76 2.6 Discussion 86 2 2.7 Acknowledgements 92 2.8 Appendix 93 2.9 References 93 3 Paper 2: Subvisible aggregates of immunogenic proteins promote a Th1-type response 97 3.1 Abstract 99 3.2 Introduction 100 3.3 Materials and Methods 103 3.4 Results 108 3.5 Discussion 124 3.6 Acknowledgements 129 3.7 Supplementary data 130 3.8 References 131 4 Paper 3: Influence of E.coli chaperone DnaK on protein immunogenicity 136 4.1 Abbreviations 138 4.2 Abstract 139 4.3 Introduction 140 4.4 Methods 143 4.5 Results 148 4.6 Discussion
    [Show full text]
  • MSD 96-Well MULTI-ARRAY Bio-Process Assay Summary
    MSD® 96-Well MULTI-ARRAY® Bio-Process Assay CHO Host Cell Protein Assay Summary MSD’s bioprocess assays are designed for single and multiplex measurements of common bioprocess contaminants. Assays for several common contaminants including insulin, methotrexate (MTX), host cell proteins, and protein A are currently available. This insert describes how to run the CHO Host Cell Protein assay independently. MSD offers additional kits for CHO Host Cell Protein multiplexed with Protein A or with insulin and MTX. Comments on the assay Currently, MSD offers assays for host cell proteins from Chinese hamster ovary (CHO) and E.Coli cells. The polyclonal antibodies used in these immunoassays were raised against a lysate of washed cells. These assays can be run either with the HCP Calibrator supplied or with a customer-supplied Calibrator (e.g. from a mock bioprocess run). Calibrators provided by MSD for HCP assays are solubilized with a detergent. The Diluent 21 that the Calibrators are diluted in includes this detergent. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES. 17370-v3-2009Sep Reagents Provided Storage MULTI-ARRAY or 96-well MSD plate spotted with ® 2-8 oC MULTI-SPOT Plate specific capture antibodies Detection Antibodies labeled with CHO HCP Detection SULFO-TAG reagent. These 2-8 oC Antibody antibodies are supplied at 50X concentration Read Buffer T 4X Read Buffer T with surfactant RT Buffered solution containing blocking Diluent 21 and stabilizing agents in addition to ≤ -10 oC detergents CHO HCP Calibrator
    [Show full text]
  • EUROPEAN PHARMACOPOEIA Free Access to Supportive Pharmacopoeial Texts in the Field of Vaccines for Human Use During the Coronavirus Disease (COVID-19) Pandemic
    EUROPEAN PHARMACOPOEIA Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package - October 2020 Published in accordance with the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50) European Directorate Direction européenne for the Quality de la qualité of Medicines du médicament & HealthCare & soins de santé Council of Europe Strasbourg Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package The EDQM is committed to supporting users during the coronavirus disease (COVID-19) pandemic – as well as contributing to the wider global effort to combat the virus – by openly sharing knowledge and providing access to relevant guidance/standards. To support organisations involved in the development, manufacture or testing of COVID-19 vaccines worldwide, many of which are universities and small and medium-sized enterprises, the EDQM is offeringte mporary free access to texts of the European Pharmacopoeia (Ph. Eur.) in the field of vaccines. This package includes quality standards for vaccines which developers can take into account to help build appropriate analytical control strategies for their COVID-19 candidate vaccines and ensure the quality and safety of the final product. Application of such quality requirements may ultimately help to facilitate regulatory acceptance of a subsequent marketing authorisation application. For ease of reading, a summary table listing the pharmacopoeial texts, with information regarding the vaccine types or vaccine platforms concerned (e.g. live attenuated viral vaccine, recombinant viral-vectored vaccines) is provided.
    [Show full text]
  • Bioprecess/Vaccine (HCP) Contaminats Detection and Removal ELISA Kits
    Bioprecess/Vaccine (HCP) Contaminats Detection and Removal ELISA Kits Vaccines are among the greatest achievements of modern medicine. Vaccines are derived from either whole cells (bacteria or virus; live or attenuated) grown in chick embryo or in mammalian host cells. Subunit vaccines may be recombinant proteins expressed in E. coli or year or other host cells. Depending upon the source of the material, purified active vaccine components may still have remnants of the host (cellular proteins or host cell proteins or HCP, culture medium proteins (Fetal bovine serum or BSA, or Fetuin etc). These extraneous proteins or components are typically known host cell contaminants. FDA requires that the finished vaccine material be tested for the appropriate contaminant and their concentration kept to an acceptable level. Many additives or excipients (Proteins, bacteriostatic agents or adjuvants) are added to stabilize the vaccines or to enhance antigenicity (adjuvants). Elevated levels of the contaminants may be allergenic (ovalbumin) or carry risk of prophylaxis due to the production of antibodies to foreign proteins or risk of animal or human derived diseases. Excipient/Contaminants Use Vaccine (Brand) Albumin Egg (Ovalbumin or OVA) Rabies Virus Grown Rabies (RabAvert) chick embryo fibroblast Albumin, Human serum (HSA) Growth medium, protein Measles (attenuvax), MMR (MMR-II), Mumps (Mumpsvax), Rabies (Imovax), stabilizer Rubella (Meruvax) Albumin, Bovine serum (BSA) Growth medium, protein Hepatitis A (Harvix, Vaqta); Measles (Attenuvax), MMR
    [Show full text]
  • Immunoenzymetric Assay for the Measurement of MRC5 Host Cell Proteins Catalog # F300
    MRC5 Host Cell Proteins Immunoenzymetric Assay for the Measurement of MRC5 Host Cell Proteins Catalog # F300 Intended Use with essentially all of the HCPs that could pollute the product independent of the purification process. The This kit is intended for use in determining the presence antibodies have been generated against and affinity of MRC5 host cell protein impurities in products purified using a mild lysate washed of MRC5 cells to manufactured by recombinant expression in MRC5 cells. obtain HCPs typically encountered in your initial product The kit is for Research and Manufacturing Use Only recovery step. Western blot was used as a preliminary and is not intended for diagnostic use in humans or method and established that the antibodies reacted to animals. the majority of HCP bands resolved by the PAGE separation. If you have need of a more sensitive and specific method to demonstrate reactivity to individual Summary and Explanation HCPs in your samples If you have a need of a more sensitive method to demonstrate coverage to HCPs in Recombinant protein expression or virus replication in your process Cygnus Technologies recommends a the MRC5 cell line is a cost effective method for method that is superior to Western blot called Antibody production of vaccines or other therapeutic proteins. Affinity Extraction (AAE). AAE is has greatly increased Many of these products are intended for use as sensitivity and specificity to Western blot which makes it therapeutic agents in humans and animals and as such a better predictor of how the antibodies will perform in must be highly purified. The manufacturing and the ELISA.
    [Show full text]
  • Protein Metrics Solutions
    Vendor Neutral Host Cell Protein Analysis Regulator Positions on HCPs – VERY CLEAR • Regulators classify residual host cell proteins (HCPs) as “process-related impurities” [ICH Q6B, Q2B]. • ‘Finding’, ‘measuring’ and ‘monitoring’ are key guideline elements • EMA from 1997: ‘The ability of the purification process to remove other specific contaminants such as host-cell proteins … should be demonstrated’ • USFDA biosimilar guidelines 2012: “In all cases, the chosen analytical procedures should be adequate to detect, identify, and accurately quantify biologically significant levels of impurities (see ICH Q2B)”. http://www.fda.gov/downloads/drugs/guidancecomplianceregula http://www.ema.europa.eu/docs/en_GB/document_librar toryinformation/guidances/ucm073488.pdf y/Scientific_guideline/2009/09/WC500003947.pdf Before there was Mass Spectrometry… Points at which Cost Savings Can be Made with HCP Analysis Upstream: ‘Catalogue’ of HCPs/ contaminants – Save Millions of dollars over product lifecycle and multiple cell lines Image source: Ratcliff and Preisig 2013; BioProcess International; http://www.bioprocessintl.com/journal/2013/April/Ad vances-in-Sensor-Technology-Improve- Biopharmaceutical-Development-341848 Points at which Cost Savings Can be Made with HCP Analysis Upstream: ‘Catalogue’ of HCPs/ contaminants – Save Millions of dollars over product lifecycle and multiple cell lines Improved ELISA assays (better specificity) – hundreds of thousands of dollars in avoided recall per batch Image source: Ratcliff and Preisig 2013; BioProcess International;
    [Show full text]